ARMS法和Sanger测序法检测晚期肺腺癌小标本EGFR基因突变分析  

Analysis of EGFR mutations in small specimen of advanced lung adenocarcinoma by ARMS and Sanger sequencing methods

作　　者：梁继珍 苏宁[2] 谢亚琳[2] 易基群 LIANG Jizhen;SU Ning;XIE Yalin;YI Jiqun(Department of Oncology,Guangzhou Red Cross Hospital,Guangzhou 510220,China)

机构地区：[1]广州市红十字会医院肿瘤科,广州510220 [2]广州市胸科医院肿瘤科,广州510095

出　　处：《实用医学杂志》2018年第13期2104-2107,2118,共5页The Journal of Practical Medicine

基　　金：广东省医学科研基金(编号:B2016112)

摘　　要：目的应用ARMS法和Sanger测序法检测晚期肺腺癌小标本组织表皮生长因子受体(EGFR)基因突变的情况并比较其一致性。方法分别使用ARMS法和测序法检测102、138例晚期肺腺癌小标本的EGFR基因突变情况,并分析其与患者临床病理特征的关系,比较其间的一致性。结果 ARMS法及测序法检测EGFR基因突变率分别为46.1%(47/102)、37.7%(52/138),ARMS法EGFR基因突变率女性高于男性(61.9%vs 35.0%,P=0.007),而与年龄、吸烟、活检部位、活检方法、标本性质、原发肿瘤、淋巴结、远处转移、分期无关(P>0.05)。测序法EGFR基因突变率与活检部位存在相关性(P=0.049),与其他临床病理特征均无关(P>0.05)。二者的一致率为64.1%(25/39),Kappa系数为0.499(P<0.001)。结论 ARMS法与测序法对晚期肺腺癌的临床小样本进行EGFR检测具有中等的一致性。Objective To analyze EGFR mutation by the Sanger sequencing and ARMS methods,and compare the consistency between them.Methods EGFR mutations in 102 cases,138 cases small specimens of advanced lung adenocarcinoma were detected by those two methods respectively,and the correlation between EGFR mutation and clinical pathologic features was analyzed.The consistency between them was measured in 39 cases.Results EGFR mutation was identified in 47(46.1%)of 102 patients by ARMS method,and was significantly higher in the female(61.9%vs 35.0%,P=0.007).While EGFR mutation by sequencing method was 37.7%(52/138),and no relationship was found with clinical pathologic features except biopsy sites(P=0.049).The consis-tency of EGFR mutation between them was 64.1%(25/39),Kappa coefficient was equal to 0.499(P<0.001).Conclusion The EGFR mutation by those two methods in small specimen of advanced lung adenocarcinoma has medium consistency.

关 键 词：肺肿瘤 腺癌 表皮生长因子受体 ARMS法 Sanger测序法 

分 类 号：R734.2[医药卫生—肿瘤]